US EditionPublished • loading... • Updated
Josh Brown: Biotech growth stocks immune to disruption risk
Summary by 247wallst.com
1 Articles
1 Articles
Josh Brown: Biotech growth stocks immune to disruption risk
Quick Read Large-cap biotech stocks face patent cliffs and biosimilar competition rather than AI-driven disruption, but companies like Amgen and AbbVie with broad product portfolios and multi-year pipeline replacements can navigate structural revenue erosion that slower innovators cannot survive. Finally! You can open a SoFi Crypto account and access 25 plus cryptocurrencies without juggling apps or logins. Josh Brown, CEO of Ritholtz Wealth M…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
